30 closest matches · ranked by relevance
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
Vestibular Schwannoma · NF2 · Neurofibromatosis 2
Primary: Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection — 3149 ng/mL
Neurofibromatosis Type 2 · Progressive Vestibular Schwannomas
Primary: Improvement in Hearing — 9 Participants
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants
Neurofibromatosis Type 2 · Vestibular Schwannomas
Primary: Expression Levels of p-S6 Based Immunohistochemistry (Histoscore) — 90 score
Siderosis · Neurological Disorder · Rare Diseases
Primary: Hearing Evaluation - Pure Tone Audiometry — 57.3 decibel hearing level
Neurofibromatosis 2 · Progressive Vestibular Schwannoma (VS)
Primary: Volumetric Response Rate — 0; 9 Participants
Dizziness · Brain Injury
Primary: Peripheral Vestibular Function (Vestibulo-ocular Reflex/Semicircular Canal): Caloric Weakness — 8.8; 14.7; 12.3; 7.1 percentage of caloric weakness
Unilateral Acoustic Neuroma · Meniere's Disease
Primary: Change in Consonant-Nucleus-Consonant (CNC) Words Scores Over Time — 23.6; 22; 18.8; 42.7 Percentage of words correct
Dizziness
Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale
Meniere's Disease
Primary: Vestibular "Endolymphatic Hydrops (EH)" — 0; 4; 2 participants
Acute Unilateral Vestibulopathy (AUV)
Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466
Parkinson's Disease
Primary: Change From Baseline in the Nonmotor Symptom Severity Scale (NMSS) — -33.5; -2.0 change in scale total score — p=0.0089
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
Vestibular Disorder · Hearing Impaired Children
Primary: Number of Hearing-impaired Infants in Flanders With Abnormal Vestibular Screening Results. — 35 Participants
Vestibular Diseases
Primary: Vestibulo-ocular Reflex Gain Ratio — 1.15 unitless gain ratio — p=<0.001
Balance Disorder
Primary: Change in Balance Performance — 0.52; 0.42; 0.51; 0.48 degrees per second
Pulsatile Tinnitus
Primary: Change From Baseline in Pulsatile Tinnitus Symptom Intensity — 3 units on a scale — p=<0.0001
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas
Meniere's Disease
Primary: Vertigo Attacks — 16.4; 19.93; 1.6; 2.5 Vertigo Attacks — p=0.271
Meniere's Disease
Primary: The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12). — 2.191; 2.415 Definitive Vertigo Day — p=0.623
Tinnitus
Primary: Number of Participants With Serious Adverse Events — 1; 2 participants
Obesity
Primary: Percentage Change of Weight From Baseline — -2.46; -1.97 Percentage change from baseline
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
Healthy Young Adults
Primary: Visuomotor Skill — 1; 1; 0.870; 0.969 Ratio of the baseline value — p=0.0096
Meniere Disease
Primary: 28-Day Average DVD at Week 12 (Month 3) — 2.869; 3.577 DVD — p=0.312
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants
Insomnia · Sleeplessness · Transient Insomnia
Primary: Latency to Persistent Sleep (LPS) — 48.14; 58.84 minutes — p=.1275